Format

Send to

Choose Destination
Retrovirology. 2016 Apr 1;13:21. doi: 10.1186/s12977-016-0251-3.

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Author information

1
ETRAV Laboratory, Faculty of Pharmacy, Centre National de la Recherche Scientifique (CNRS), Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France. erwann.loret@univ-amu.fr.
2
ETRAV Laboratory, Faculty of Pharmacy, Centre National de la Recherche Scientifique (CNRS), Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France.
3
Pharmacie Usage Interne, AP-HM, UHC «la Conception», 147 Bd Baille, 13385, Marseille, France.
4
Centre de Pharmacologie Clinique et Evaluations Thérapeutiques (AP-HM), UHC «la Timone», 28 Boulevard Jean Moulin, 13385, Marseille, France.
5
Centre d'Investigation Clinique, Assistance Publique -Hôpitaux de Marseille (AP-HM), University Hospital Center (UHC) «la Conception», 147 Bd Baille, 13385, Marseille, France.
6
Unité Mixte de Recherche CNRS 5251, Institut de Mathématique de Bordeaux, CNRS, Bordeaux 2 University, 33000, Bordeaux, France.

Abstract

BACKGROUND:

A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were randomized in double-blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. The volunteers then underwent a structured treatment interruption between M5 and M7.

RESULTS:

The primary outcomes of this phase I/IIa clinical trial were the safety and lowering the extent of HIV RNA rebound after cART interruption. Only one undesirable event possibly due to vaccination was observed. The 33 µg dose was most effective at lowering the extent of HIV RNA and DNA rebound (Mann and Whitney test, p = 0.07 and p = 0.001). Immune responses against Tat were increased at M5 and this correlated with a low HIV RNA rebound at M6 (p = 0.01).

CONCLUSION:

This study suggests in vivo that extracellular Tat activates and protects HIV infected cells. The Tat Oyi vaccine in association with cART may provide an efficient means of controlling the HIV-infected cell reservoir.

KEYWORDS:

ART interruption; Clinical trial; HIV; Tat; Vaccine

PMID:
27036656
PMCID:
PMC4818470
DOI:
10.1186/s12977-016-0251-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center